Large trials in type 2 diabetes showed that intensive glucose lowering towards normal HbA1c can be harmful: ACCORD was stopped after intensive therapy raised all-cause mortality by 22%, and severe hypoglycaemia was associated with roughly doubled mortality.
Original statement
التجارب الكبرى مثل ACCORD أوقفت العلاج المكثف مبكرًا بعد أن رفع الوفيات 22%، وأظهر تحليل Bonds أن نقص السكر الحاد المصحوب بأعراض ضاعف الوفيات في ذراعَي الدراسة.
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
Large trials in type 2 diabetes showed that intensive glucose lowering towards normal HbA1c can be harmful: ACCORD was stopped after intensive therapy raised all-cause mortality by 22%, and severe hypoglycaemia was associated with roughly doubled mortality.
Origin
- Source status
- Archive editors
- Attribution
- Archive editors (not Elawady)
- Origin
- https://eltayebat.com/rule/insulin-injections/
- Attribution uncertainty
- Editorial narrative and study selection written by the archive operators.
- Claimed mechanism
Over-intensification causes hypoglycaemia and other harms.
- Claimed health effect
Higher mortality, severe hypoglycaemia, weight gain
- Population concerned
High-risk, long-standing type 2 diabetes
- Geographic restriction by Elawady
none found
Diverging source versions
- Source status
- Archive editors
- Attribution
- Archive editors (not Elawady)
- Origin
- https://eltayebat.com/rule/oral-diabetes-drugs/
- Attribution uncertainty
- Editorial narrative and study selection written by the archive operators.
Scientific assessment
Mostly true – Correct at its core, but with limitations or minor inaccuracies.
Certainty of evidence: high – Further research is very unlikely to change the assessment.
1. What was claimed?
Intensive glucose lowering in type 2 diabetes increased mortality (ACCORD) and severe hypoglycaemia is linked to death.
2. What is demonstrably correct?
ACCORD: 10,251 patients, target HbA1c <6.0%: 257 vs 203 deaths, HR 1.22 (95% CI 1.01-1.46); the intensive arm was stopped after 3.5 years; no significant reduction of the primary cardiovascular outcome (HR 0.90) (A-INS-01). Full text reports death from cardiovascular causes HR 1.35 (1.04-1.76), so the archive's 35% figure is correct. VADT found no benefit on major cardiovascular events or death (HR 1.07) and more adverse events, mainly hypoglycaemia (A-INS-03). Severe hypoglycaemia was associated with higher mortality in ACCORD (adjusted HR 1.41 intensive, 2.30 standard arm) (A-INS-14) and with macrovascular events (HR 2.88) and death (HR 2.69) in ADVANCE (A-INS-15). In critically ill patients, tight glucose control (4.5-6.0 mmol/L) increased 90-day mortality (A-INS-02). ADA 2026 states that clinicians 'should not aggressively attempt to achieve near-normal A1C levels' where this cannot be done safely (I-INS-10).
3. What is wrong or exaggerated?
The archive's Arabic headline attributes the ACCORD harm to 'high insulin doses'; ACCORD tested a treatment strategy using many drugs (in the intensive arm 94.7% metformin, 91.7% thiazolidinedione, 86.6% secretagogue and 77.3% any insulin, per full text) and could not attribute the excess mortality to any single drug. Bonds et al. explicitly concluded that hypoglycaemia did not appear to account for the mortality difference between arms (A-INS-14). ADVANCE (target HbA1c <=6.5%) found a 10% reduction in combined major macro- and microvascular events, mainly nephropathy, and no increase in death (HR 0.93) (I-INS-01). UKPDS showed microvascular benefit (A-INS-16) and long-term reductions of myocardial infarction and death (I-INS-02); in type 1 diabetes intensive insulin therapy reduced retinopathy by 76% (I-INS-03). The archive's statement that severe hypoglycaemia doubled mortality 'in both arms' is correct only for the standard arm (adjusted HR 2.30); in the intensive arm the adjusted HR was 1.41 (A-INS-14).
4. What remains unclear?
The exact mechanism of excess death in ACCORD remains unexplained.
5. Which studies support it?
A-INS-01, A-INS-02, A-INS-03, A-INS-14, A-INS-15, I-INS-10.
6. Which studies contradict it?
I-INS-01, I-INS-02, I-INS-03, A-INS-16 (benefits of good, non-extreme control).
7. What applies to Germany and Europe?
European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.
8. What is known about Egypt?
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
9. What practical conclusion is appropriate?
This part of the archive is accurate and matches current guidelines: HbA1c targets should be individualised (often <7%), less strict for frail or older people, and treatment should avoid hypoglycaemia. It does not support the conclusion that lowering high blood glucose is harmful in general.
Assessment details
- Rationale for certainty of evidence
Directly reported RCT results (ACCORD abstract; cardiovascular death HR 1.35 confirmed in full text). Consistent with VADT, ADVANCE and current guidelines. Downgraded from TRUE because the archive omits that ADVANCE showed microvascular benefit, that hypoglycaemia did not explain the ACCORD mortality excess, and that the harm concerned a near-normal target in high-risk patients, not glucose lowering in general.
- Source quality
Archive editorial correctly quoting RCTs.
- Regional transferability
Trials were multinational (US/Canada, ADVANCE incl. Europe/Asia); transferable.
- Individual exceptions
Younger people early in the disease without cardiovascular disease may benefit from lower targets if achieved safely (ADA 2026, I-INS-10).
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 25 October 2026 provisional
In plain language
Very large studies tested whether pushing blood sugar down to almost normal levels helps people with long-standing type 2 diabetes and heart risk. In one study (ACCORD), more people died with the very aggressive approach, and very low blood sugar episodes were linked to death. Other studies showed that good but not extreme control protects the kidneys, eyes and nerves. Doctors therefore now set personal targets and try to avoid low blood sugar.
Studies on this claim
Studies supporting the claim (8)
-
Very aggressive blood sugar lowering in high-risk type 2 diabetes
Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743Randomised controlled trialcited by the Tayebat archivefull text checked★ key studyPushing HbA1c below 6% increased deaths by about one-fifth and did not reduce heart attacks or strokes significantly.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Does targeting a normal HbA1c (<6.0%) reduce cardiovascular events in type 2 diabetes with high cardiovascular risk?
- How was the study done?
Multicentre randomised controlled trial (open-label treatment strategies), mean 3.5 years of intensive therapy
- How many people, animals or samples were studied?
10,251; Type 2 diabetes, mean age 62.2, median HbA1c 8.1%, established CVD or additional risk factors
- What was actually found?
More deaths (HR 1.22) and more severe hypoglycaemia with intensive therapy; primary CV outcome not significantly reduced.
- How large was the observed effect?
HR 1.22 (1.01-1.46) all-cause death; HR 0.90 (0.78-1.04) primary outcome
- What do the results mean in everyday life?
Very strict sugar targets are not good for everyone, especially older people with heart disease.
- What are the study's limitations?
Strategy trial: cannot attribute harm to a specific drug; Intensive arm stopped early; High-risk population; not generalisable to early diabetes
- What does it say about Elawady's specific claim?
Core evidence that near-normal HbA1c targets can harm high-risk type 2 patients (C-INS-04).
- Do the results apply to Germany and Europe?
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
- What can explicitly not be concluded from this study?
That insulin specifically caused the deaths, or that lowering high glucose to moderate targets is harmful.
-
Very tight blood sugar control in intensive care
NICE-SUGAR Study Investigators; Finfer S et al.. N Engl J Med 2009 · PMID 19318384 · DOI 10.1056/NEJMoa0810625Randomised controlled trialcited by the Tayebat archiveabstract only checkedAiming for normal blood sugar in ICU patients raised deaths from 24.9% to 27.5%.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Optimal blood glucose target in critically ill ICU patients
- How was the study done?
International multicentre RCT
- How many people, animals or samples were studied?
6,104; Adult ICU patients expected to stay >=3 days
- What was actually found?
Higher 90-day mortality and 13-fold more severe hypoglycaemia with intensive control.
- How large was the observed effect?
OR 1.14 (1.02-1.28)
- What do the results mean in everyday life?
In very sick hospital patients, moderate sugar targets are safer.
- What are the study's limitations?
ICU population, not ambulatory diabetes; Open-label
- What does it say about Elawady's specific claim?
Supports that overly tight targets harm (C-INS-04); both arms received insulin, so it does not support insulin avoidance.
- Do the results apply to Germany and Europe?
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
- What can explicitly not be concluded from this study?
Anything about insulin therapy in people with diabetes at home.
-
Intensive sugar control in veterans with long diabetes
Duckworth W et al.. N Engl J Med 2009 · PMID 19092145 · DOI 10.1056/NEJMoa0808431Randomised controlled trialcited by the Tayebat archiveabstract only checkedLower sugar did not reduce heart events or deaths, and side effects (mainly hypoglycaemia) were more frequent.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Effect of intensive glucose control on CV events in long-standing type 2 diabetes
- How was the study done?
Multicentre RCT
- How many people, animals or samples were studied?
1,791; Military veterans, mean age 60.4, diabetes 11.5 years, 40% prior CV event
- What was actually found?
No significant reduction in CV events or death; more adverse events.
- How large was the observed effect?
HR 0.88 (0.74-1.05) primary; HR 1.07 death
- What do the results mean in everyday life?
In long-standing diabetes, very intensive control brings little benefit and more low-sugar episodes.
- What are the study's limitations?
Smaller sample, limited power; Mostly men
- What does it say about Elawady's specific claim?
Supports C-INS-04 (no CV benefit, more hypoglycaemia).
- Do the results apply to Germany and Europe?
US veterans; transferable with caution (mostly men).
- What can explicitly not be concluded from this study?
That moderate glucose control is useless or that insulin causes death.
-
Severe low blood sugar and death in ACCORD
Bonds DE et al.. BMJ 2010 · PMID 20061358 · DOI 10.1136/bmj.b4909Cohort studycited by the Tayebat archivefull text checked★ key studyPeople who had severe low-sugar episodes died more often, but this did not explain why the intensive group had more deaths.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Link between severe hypoglycaemia and mortality in ACCORD
- How was the study done?
Retrospective epidemiological analysis within an RCT (ACCORD)
- How many people, animals or samples were studied?
10,194; ACCORD participants with hypoglycaemia assessment
- What was actually found?
Deaths were more common after severe low-sugar episodes (adjusted HR 1.41 and 2.30), but only 1 of 451 deaths was definitely caused by low sugar, and it explained only about 5 of 57 extra deaths in the intensive group.
- How large was the observed effect?
aHR 1.41 (1.03-1.93) intensive arm
- What do the results mean in everyday life?
Severe hypoglycaemia is a danger sign to avoid.
- What are the study's limitations?
Post-hoc observational analysis; Confounding by frailty
- What does it say about Elawady's specific claim?
Supports C-INS-04 (hypoglycaemia is a marker of risk); limits causal interpretation.
- Do the results apply to Germany and Europe?
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
- What can explicitly not be concluded from this study?
That hypoglycaemia caused the ACCORD excess mortality.
-
Severe hypoglycaemia in ADVANCE
Zoungas S et al.. N Engl J Med 2010 · PMID 20925543 · DOI 10.1056/NEJMoa1003795Cohort studycited by the Tayebat archivefull text checkedSevere low-sugar episodes were followed by more heart events and deaths, probably partly because frail people get them.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Severe hypoglycaemia and vascular events/death
- How was the study done?
Post-hoc cohort analysis of an RCT (ADVANCE)
- How many people, animals or samples were studied?
11,140; ADVANCE participants with type 2 diabetes
- What was actually found?
aHR 2.69 death.
- How large was the observed effect?
aHR 2.69 (1.97-3.67)
- What do the results mean in everyday life?
Avoid severe hypoglycaemia.
- What are the study's limitations?
Only 231 people had severe hypoglycaemia; links also seen with skin and digestive disease (suggesting frailty); no dose-response; intensive treatment was a sulfonylurea, not insulin; funded by the drug's manufacturer.
- What does it say about Elawady's specific claim?
- Do the results apply to Germany and Europe?
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
- What can explicitly not be concluded from this study?
Causation.
-
Very aggressive blood sugar lowering in high-risk type 2 diabetes
Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743Randomised controlled trialcited by the Tayebat archivefull text checked★ key studyPushing HbA1c below 6% increased deaths by about one-fifth and did not reduce heart attacks or strokes significantly.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Does targeting a normal HbA1c (<6.0%) reduce cardiovascular events in type 2 diabetes with high cardiovascular risk?
- How was the study done?
Multicentre randomised controlled trial (open-label treatment strategies), mean 3.5 years of intensive therapy
- How many people, animals or samples were studied?
10,251; Type 2 diabetes, mean age 62.2, median HbA1c 8.1%, established CVD or additional risk factors
- What was actually found?
More deaths (HR 1.22) and more severe hypoglycaemia with intensive therapy; primary CV outcome not significantly reduced.
- How large was the observed effect?
HR 1.22 (1.01-1.46) all-cause death; HR 0.90 (0.78-1.04) primary outcome
- What do the results mean in everyday life?
Very strict sugar targets are not good for everyone, especially older people with heart disease.
- What are the study's limitations?
Strategy trial: cannot attribute harm to a specific drug; Intensive arm stopped early; High-risk population; not generalisable to early diabetes
- What does it say about Elawady's specific claim?
Core evidence that near-normal HbA1c targets can harm high-risk type 2 patients (C-INS-04).
- Do the results apply to Germany and Europe?
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
- What can explicitly not be concluded from this study?
That insulin specifically caused the deaths, or that lowering high glucose to moderate targets is harmful.
-
Intensive sugar control in veterans with long diabetes
Duckworth W et al.. N Engl J Med 2009 · PMID 19092145 · DOI 10.1056/NEJMoa0808431Randomised controlled trialcited by the Tayebat archiveabstract only checkedLower sugar did not reduce heart events or deaths, and side effects (mainly hypoglycaemia) were more frequent.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Effect of intensive glucose control on CV events in long-standing type 2 diabetes
- How was the study done?
Multicentre RCT
- How many people, animals or samples were studied?
1,791; Military veterans, mean age 60.4, diabetes 11.5 years, 40% prior CV event
- What was actually found?
No significant reduction in CV events or death; more adverse events.
- How large was the observed effect?
HR 0.88 (0.74-1.05) primary; HR 1.07 death
- What do the results mean in everyday life?
In long-standing diabetes, very intensive control brings little benefit and more low-sugar episodes.
- What are the study's limitations?
Smaller sample, limited power; Mostly men
- What does it say about Elawady's specific claim?
Supports C-INS-04 (no CV benefit, more hypoglycaemia).
- Do the results apply to Germany and Europe?
US veterans; transferable with caution (mostly men).
- What can explicitly not be concluded from this study?
That moderate glucose control is useless or that insulin causes death.
-
ADA guideline 2026: blood sugar goals and emergencies
American Diabetes Association Professional Practice Committee for Diabetes* . Diabetes Care 2026 · PMID 41358894 · DOI 10.2337/dc26-S006Guideline / position statementindependent cross-checkfull text checked★ key studyMost adults should aim for HbA1c below 7%, avoid low sugar, and measure ketones when at risk.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Glycaemic goals, hypoglycaemia and hyperglycaemic crises
- How was the study done?
Clinical practice guideline (ADA Standards of Care 2026, Section 6)
- How many people, animals or samples were studied?
not applicable; People with diabetes
- What was actually found?
Individual targets; do not stop basal insulin when not eating.
- How large was the observed effect?
not applicable
- What do the results mean in everyday life?
Moderate targets and safety rules.
- What are the study's limitations?
US-centred; Partially read
- What does it say about Elawady's specific claim?
Supports C-INS-04, C-INS-11; contradicts C-FAST-01, C-FAST-03, C-DIAB-02.
- Do the results apply to Germany and Europe?
Consistent with EASD guidance.
- What can explicitly not be concluded from this study?
Not applicable.
No study in this group is marked as key.
Studies contradicting or limiting the claim (3)
-
ADVANCE: intensive control to HbA1c 6.5%
ADVANCE Collaborative Group; Patel A et al.. N Engl J Med 2008 · PMID 18539916 · DOI 10.1056/NEJMoa0802987Randomised controlled trialindependent cross-checkfull text checked★ key studyFewer kidney complications and no extra deaths, but more severe hypoglycaemia.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Effect of intensive glucose control (gliclazide MR-based, HbA1c <=6.5%) on vascular outcomes
- How was the study done?
Multicentre factorial RCT (ADVANCE glucose arm)
- How many people, animals or samples were studied?
11,140; Type 2 diabetes with high vascular risk
- What was actually found?
10% fewer combined events; no mortality difference.
- How large was the observed effect?
HR 0.90 (0.82-0.98)
- What do the results mean in everyday life?
Moderately intensive control is safe and protects kidneys.
- What are the study's limitations?
Open-label; kidney benefit mainly less protein in urine; underpowered for heart attacks/strokes; funded by the drug's manufacturer (analysis independent).
- What does it say about Elawady's specific claim?
Limits C-INS-04 (intensive control is not uniformly harmful); contradicts C-ODD-11.
- Do the results apply to Germany and Europe?
Multinational trial including European sites or directly applicable to EU practice.
- What can explicitly not be concluded from this study?
Benefit for heart attacks/stroke.
-
UKPDS legacy: 10 years after the trial
Holman RR et al.. N Engl J Med 2008 · PMID 18784090 · DOI 10.1056/NEJMoa0806470Randomised controlled trialindependent cross-checkabstract only checked★ key studyPeople treated intensively early with sulfonylureas or insulin had 15% fewer heart attacks and 13% fewer deaths years later.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Do UKPDS benefits persist and do macrovascular effects emerge?
- How was the study done?
Post-trial monitoring of an RCT (UKPDS 80)
- How many people, animals or samples were studied?
4,209 randomised; 3,277 monitored; Newly diagnosed type 2 diabetes from UKPDS
- What was actually found?
Legacy reductions in MI and death.
- How large was the observed effect?
Death -13% (SU/insulin), -27% (metformin)
- What do the results mean in everyday life?
Early good control pays off for decades.
- What are the study's limitations?
Post-trial therapy not controlled; Questionnaire follow-up
- What does it say about Elawady's specific claim?
Contradicts C-INS-03, C-INS-05 and C-DIAB-01: early insulin/SU therapy reduced MI and death long-term.
- Do the results apply to Germany and Europe?
UK; directly relevant.
- What can explicitly not be concluded from this study?
Effects of extreme targets in late disease.
-
DCCT: better insulin treatment in type 1 diabetes
Diabetes Control and Complications Trial Research Group; Nathan DM et al.. N Engl J Med 1993 · PMID 8366922 · DOI 10.1056/NEJM199309303291401Randomised controlled trialindependent cross-checkabstract only checked★ key studyIntensive insulin cut the risk of eye damage by three-quarters and nerve damage by 60%, with more low-sugar episodes.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Does intensive insulin therapy reduce long-term complications in type 1 diabetes?
- How was the study done?
Multicentre RCT (DCCT)
- How many people, animals or samples were studied?
1,441; Insulin-dependent (type 1) diabetes
- What was actually found?
Large reductions in all microvascular complications.
- How large was the observed effect?
Retinopathy -76%
- What do the results mean in everyday life?
Insulin protects eyes, kidneys and nerves in type 1 diabetes.
- What are the study's limitations?
Open-label; Selected young population
- What does it say about Elawady's specific claim?
Contradicts C-INS-07, C-INS-09, C-DIAB-01; shows insulin efficacy and hypoglycaemia cost (C-INS-02 kernel).
- Do the results apply to Germany and Europe?
North American; universally accepted.
- What can explicitly not be concluded from this study?
Effects in type 2 diabetes directly.
No study in this group is marked as key.
Studies with mixed or unclear results (1)
-
UKPDS: tablets or insulin for new type 2 diabetes
UKPDS Group. Lancet 1998 · PMID 9742976Randomised controlled trialcited by the Tayebat archiveabstract only checked★ key studyBetter sugar control with tablets or insulin cut eye/kidney complications by a quarter; insulin caused more weight gain and low-sugar episodes.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Intensive control with sulfonylurea or insulin vs diet on complications
- How was the study done?
Multicentre RCT (UKPDS 33)
- How many people, animals or samples were studied?
3,867; Newly diagnosed type 2 diabetes, median age 54
- What was actually found?
Microvascular -25%; more hypoglycaemia and weight gain with insulin.
- How large was the observed effect?
RR reduction 25% microvascular
- What do the results mean in everyday life?
Insulin helps prevent complications but has side effects.
- What are the study's limitations?
Open-label; Older drug regimens
- What does it say about Elawady's specific claim?
Supports weight/hypoglycaemia (C-INS-01); contradicts C-INS-03, C-INS-05, C-DIAB-01.
- Do the results apply to Germany and Europe?
UK; directly relevant.
- What can explicitly not be concluded from this study?
That insulin is harmful overall.
No study in this group is marked as key.
Regional context
Germany / EU
European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.
Egypt
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
What applies in my country?
General scientific assessment
Mostly true Correct: aggressive near-normal targets can harm high-risk type 2 patients; this supports moderate, individual targets, not abandoning treatment.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Effects of intensive glucose lowering in type 2 diabetes.. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743
- Intensive versus conventional glucose control in critically ill patients.. NICE-SUGAR Study Investigators; Finfer S et al.. N Engl J Med 2009 · PMID 19318384 · DOI 10.1056/NEJMoa0810625
- Glucose control and vascular complications in veterans with type 2 diabetes.. Duckworth W et al.. N Engl J Med 2009 · PMID 19092145 · DOI 10.1056/NEJMoa0808431
- The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.. Bonds DE et al.. BMJ 2010 · PMID 20061358 · DOI 10.1136/bmj.b4909
- Severe hypoglycemia and risks of vascular events and death.. Zoungas S et al.. N Engl J Med 2010 · PMID 20925543 · DOI 10.1056/NEJMoa1003795
- Effects of intensive glucose lowering in type 2 diabetes.. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743
- Glucose control and vascular complications in veterans with type 2 diabetes.. Duckworth W et al.. N Engl J Med 2009 · PMID 19092145 · DOI 10.1056/NEJMoa0808431
- 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes* . Diabetes Care 2026 · PMID 41358894 · DOI 10.2337/dc26-S006
- Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.. ADVANCE Collaborative Group; Patel A et al.. N Engl J Med 2008 · PMID 18539916 · DOI 10.1056/NEJMoa0802987
- 10-year follow-up of intensive glucose control in type 2 diabetes.. Holman RR et al.. N Engl J Med 2008 · PMID 18784090 · DOI 10.1056/NEJMoa0806470
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.. Diabetes Control and Complications Trial Research Group; Nathan DM et al.. N Engl J Med 1993 · PMID 8366922 · DOI 10.1056/NEJM199309303291401
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.. UKPDS Group. Lancet 1998 · PMID 9742976